Do Targeted Therapies Drive Disparities?
After the widespread use of targeted therapies for breast cancer treatment, there was a wider gap in mortality rates between black and white women with the disease.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC